[EN] 3-GUANIDINOCARBONYL-1-HETEROARYL-INDOLE DERIVATIVES, PREPARATION PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM [FR] DERIVES DE 3-GUANIDINOCARBONYLE-1-HETEROARYLE-INDOLE, PROCEDE DE PREPARATION ASSOCIE, LEUR UTILISATION COMME MEDICAMENTS, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
[EN] 3-GUANIDINOCARBONYL-1-HETEROARYL-INDOLE DERIVATIVES, PREPARATION PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM [FR] DERIVES DE 3-GUANIDINOCARBONYLE-1-HETEROARYLE-INDOLE, PROCEDE DE PREPARATION ASSOCIE, LEUR UTILISATION COMME MEDICAMENTS, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
3-Guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them
申请人:Kleemann Heinz-Werner
公开号:US20050026989A1
公开(公告)日:2005-02-03
The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, pharmaceutical compositions comprising such derivatives, methods of treatment comprising administering such derivatives, and processes for their preparation.
3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them
申请人:sanofi-aventis Deutschland GmbH
公开号:US07531663B2
公开(公告)日:2009-05-12
The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, pharmaceutical compositions comprising such derivatives, methods of treatment comprising administering such derivatives, and processes for their preparation.
[EN] 3-GUANIDINOCARBONYL-1-HETEROARYL-INDOLE DERIVATIVES, PREPARATION PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM<br/>[FR] DERIVES DE 3-GUANIDINOCARBONYLE-1-HETEROARYLE-INDOLE, PROCEDE DE PREPARATION ASSOCIE, LEUR UTILISATION COMME MEDICAMENTS, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
申请人:AVENTIS PHARMA GMBH
公开号:WO2004007480A1
公开(公告)日:2004-01-22
The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-indole derivatives of the formula (I) in which R1 to R5 and Ar have the meaning stated in the claims. The inventive compounds are suitable for example as antiarrhytmic medicaments with cardioprotective component for infarction prophylaxis and infarction treatment and for the treatment of angina pectoris. They also inhibit in a preventive manner the pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhytmias and of heart failure.